George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

TOP NEWS: GlaxoSmithKline Notes EU Approval For HIV Drug Rukobia

Mon, 08th Feb 2021 14:17

(Alliance News) - GlaxoSmithKline PLC on Monday noted ViiV Healthcare's EU marketing authorisation for drug Rukobia plus other antiretrovirals to treat multidrug-resistant HIV in adults.

ViiV is majority owned by Glaxo, with Pfizer Inc and Shionogi Ltd as shareholders. It announced the European Marketing Authorisation for Rukobia, brand name for fostemsavir, 600 milligram extended-release tablets.

The EMA approval is in combination with others antiretroviral therapies, to treat multidrug-resistant HIV-1 in adults who cannot otherwise "construct a suppressive anti-viral regimen".

Fostemsavir "works by targeting the first step of the HIV lifecycle" and at present there is no -cross-resistance to other licences classes of antiretrovirals. This means the drug is a new option for people who are resistant to multiple HIV drugs and facing "risk of disease progression and death".

This authorisation was supported by data from ViiV's pivotal phase three Brighte study. In the randomised cohort, 60% of those who received fostemsavir plus an optimised background therapy, achieves undetectable HIV viral load and a clinically significant improvement to CD4+ T-cell count through week 96.

ViiV Chief Executive Deborah Waterhouse said: ""There have been great strides forward in the treatment of HIV over the last few decades, however, there still remains a small subset of people living with multi-drug resistant HIV who are at risk of having their disease progress. The marketing authorisation for fostemsavir marks a significant milestone, as it addresses a critical unmet need in HIV care for those with little or no treatment options left. At ViiV Healthcare, through our pioneering research and development, we aim to meet the diverse needs of the HIV community. We won't stop until our research offers more ways to treat, and hopefully one day, cure HIV."

Shares in Glaxo were up 1.0% at 1,279.00 pence in London on Monday afternoon.

By Anna Farley; annafarley@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent e...

18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon...

18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patien...

7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.